Shuangcheng Pharma’s Generic Bivalirudin Approved by Australia’s TGA
China-based Hainan Shuangcheng Pharmaceutical Co., Ltd (SHE: 002693) announced that the market filing for its...
Drug
Everest Medicines’ Nefecon Receives Full Approval from NMPA for IgAN Treatment
China-based Everest Medicines (HKG: 1952) announced that the National Medical Products Administration (NMPA) has converted...
CSPC’s JMT202 Receives FDA IND Approval for Hypertriglyceridemia Trials
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has secured an investigational new drug (IND) approval...
Guilin Sanjin’s BC006 Monoclonal Antibody Gains NMPA Approval for IPF Trials
Guilin Sanjin Pharmaceutical Co., Ltd. (SHE: 002275) announced that its Shanghai-based subsidiary Dragon Boat Biopharmaceutical’s...
Innovent Biologics Presents Positive IBI302 Results for nAMD at ARVO 2025
China-based Innovent Biologics, Inc. (HKG: 1801) announced the presentation of 1-year results from its Phase...
AccurEdit Therapeutics’ ART001 Shows Promising Results in ATTR Treatment
China-based gene editing therapy specialist AccurEdit Therapeutics (Suzhou) Co., Ltd. has published the latest data...
Novo Nordisk’s Once-Daily Wegovy NDA Accepted for FDA Review
Denmark-based Novo Nordisk (NYSE: NVO) announced that its New Drug Application (NDA) filing for its...
Johnson & Johnson’s Imaavy Gains FDA Approval for Generalized Myasthenia Gravis
US giant Johnson & Johnson (J&J, NYSE: JNJ) unveiled a market approval in the United...
Chengdu Origen Announces First Patient Dosing of KH658 in Wet AMD Trial
China-based Chengdu Origen Biotechnology Co., Ltd. announced the first patient dosing of KH658, a gene...
AstraZeneca’s Breztri Aerosphere Meets Primary Endpoints in Phase III Asthma Trials
UK-based pharmaceutical firm AstraZeneca (AZ; NASDAQ: AZN) this week unveiled results from the Phase III...
Alphamab and CSPC Announce Positive Interim Results for KN026 in HER2+ Gastric Cancer Trial
China-based firms Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) announced the...
Innovent Biologics Initiates First-in-Human Dosing of IBI3020 in Phase I Trial
China-based Innovent Biologics, Inc. (HKG: 1801) announced the first-in-human dosing of IBI3020, a first-in-class CEACAM5-targeted...
AbbVie’s Rinvoq Gains FDA Approval for Giant Cell Arteritis
US-based pharma giant AbbVie (NYSE: ABBV) announced regulatory approval from the US Food and Drug...
Bayer AG Launches Phase I Study of 225Ac-GPC3 for Advanced Hepatocellular Carcinoma
German pharmaceutical giant Bayer AG (ETR: BAYN) has initiated a Phase I clinical study to...
Hengrui Pharmaceuticals Receives NMPA Clearance for HRS-5635 in Chronic HBV
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical clearance...
Boehringer Ingelheim’s Zongertinib Shows Promising Results in HER2-Mutant NSCLC Trial
German pharmaceutical giant Boehringer Ingelheim has released the latest results from the Beamion LUNG-1 trial,...
Kangpu Biopharmaceuticals Receives NMPA Approval for KPG-818 Phase IIb Study in SLE
China-based Kangpu Biopharmaceuticals, Ltd announced that it has received approval from the National Medical Products...
Frontera Therapeutics’ Gene Therapy FT-017 Gains Clinical Trial Approvals for HCM
Sino-US biotech company Frontera Therapeutics, Inc. announced that its recombinant adeno-associated virus (rAAV) gene therapy...
Johnson & Johnson’s TAR-200 Shows Promising Results in Phase IIb SunRISe-1 Study for Bladder Cancer
US giant Johnson & Johnson (J&J; NYSE: JNJ) has released the first results from Cohort...
Regeneron’s Lynozyfic Gains EC Conditional Approval for Relapsed Multiple Myeloma
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that it has received conditional marketing authorization from the...